Stifel highlighted that Colgate's Hill's pet nutrition brand continues to be a strong growth driver for the company. In the fourth quarter of 2024, Hill's achieved a remarkable 25% growth, with the two-year CAGR also showing acceleration. Notably, Hill's contributed to more than 100% of Colgate's growth in scanner data tracked channels for the fourth quarter, compared to approximately 41% of the company's growth from the first to the third quarter of 2024.
The company maintains impressive gross profit margins of 60.4% and generated $20.1 billion in revenue over the last twelve months. For deeper insights into Colgate-Palmolive (NYSE:CL)'s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers this and 1,400+ other top US stocks.
The company maintains impressive gross profit margins of 60.4% and generated $20.1 billion in revenue over the last twelve months. For deeper insights into Colgate-Palmolive's financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers this and 1,400+ other top US stocks.
Stifel highlighted that Colgate's Hill's pet nutrition brand continues to be a strong growth driver for the company. In the fourth quarter of 2024, Hill's achieved a remarkable 25% growth, with the two-year CAGR also showing acceleration. Notably, Hill's contributed to more than 100% of Colgate's growth in scanner data tracked channels for the fourth quarter, compared to approximately 41% of the company's growth from the first to the third quarter of 2024.
The company maintains impressive gross profit margins of 60.4% and generated $20.1 billion in revenue over the last twelve months. For deeper insights into Colgate-Palmolive's financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers this and 1,400+ other top US stocks.
The firm's analysis included a review of recent Circana scanner data, including sales from Amazon (NASDAQ:AMZN) and Costco (NASDAQ:COST), which indicated a deceleration in Colgate's year-over-year growth to 2% in the fourth quarter of 2024, down from a year-to-date growth of 7%. Despite this slowdown, the two-year compound annual growth rate (CAGR) in the fourth quarter remained largely consistent with the levels seen in the second and third quarters of 2024.
Stifel highlighted that Colgate's Hill's pet nutrition brand continues to be a strong growth driver for the company. In the fourth quarter of 2024, Hill's achieved a remarkable 25% growth, with the two-year CAGR also showing acceleration. Notably, Hill's contributed to more than 100% of Colgate's growth in scanner data tracked channels for the fourth quarter, compared to approximately 41% of the company's growth from the first to the third quarter of 2024.
In other recent news, Colgate-Palmolive has seen significant developments. Deutsche Bank (ETR:DBKGn) recently revised the price target for the company's shares to $95 from $100, maintaining a Hold rating. The revision is due to anticipated foreign exchange headwinds and a slowdown in certain global markets. Deutsche Bank has also adjusted its earnings per share estimate for the fourth quarter of 2024 to $0.87, slightly below the consensus.
For fiscal year 2025, the bank predicts a tempered forecast due to Colgate-Palmolive's continued business investments. The company is expected to guide towards low single-digit adjusted EPS growth. The bank has also reduced the EPS forecast for 2025 to $3.65, a decrease from the previous estimate of $3.77.
In a separate development, TD Cowen reduced its price target for Colgate-Palmolive to $110 from $115, while maintaining a Buy rating. The adjustment follows the company's third-quarter results, which surpassed expectations. The firm believes that Colgate-Palmolive represents a compelling opportunity for investors seeking resilient consumer packaged goods stocks.
Stifel, another financial services firm, downgraded Colgate-Palmolive's stock from Buy to Hold, adjusting the price target to $101 from $105. The firm anticipates a deceleration in the company's organic sales growth to 4%-5% over the next four quarters. Despite this, the company's commitment to investment is noteworthy, with the 2024 estimated advertising spend projected to be around 13% of sales.
Lastly, the company's third-quarter earnings call revealed strong performance with organic sales growth across all divisions. CEO Noel Wallace expressed confidence in the company's growth strategy and innovation pipeline heading into 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.